Related Experiment Videos
Inhibition of NF-kappa B transcription factor by catechol derivatives
1Department of Molecular & Cell Biology, University of California, Berkeley 94720.
Abstract:
Therapeutic agents which target NF-kappa B transcription factor may be useful in the management of AIDS, cancer and inflammation. Since oxidative stress has been implicated in the signaling pathway, the use of antioxidants to inhibit NF-kappa B activation has gained attention. In the present study, we examined the effects of catechol derivatives, nitecapone and OR-1246, which have been identified to possess potent antioxidant properties, on NF-kappa B activation by monitoring its DNA binding activity. Both nitecapone and OR-1246 (10-300 microM) inhibited NF-kappa B activation induced by tumor necrosis factor-alpha in Jurkat T (acute human leukemia) cells. Nitecapone was a better inhibitor than OR-1246. The observed effects may, at least in part, be due to the ability of the two compounds to directly inhibit DNA binding activity of activated NF-kappa B. The inhibitory capability of OR-1246 on NF-kappa B DNA binding does not appear to be a sole mechanism, as it did not inhibit NF-kappa B activation induced by okadaic acid. Hence, catechol derivatives inhibit NF-kappa B transcription factor through multiple mechanisms, and nitecapone and OR-1246 may be useful as therapeutic agents targeting NF-kappa B.
Insights
Two antioxidant catechol derivatives, nitecapone and OR-1246, were found to inhibit nuclear factor-kappa B (NF-kappa B) activation. Nitecapone demonstrated superior inhibitory effects, suggesting potential therapeutic applications for these compounds in managing diseases like cancer and inflammation.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Nuclear factor-kappa B (NF-kappa B) is a key transcription factor implicated in AIDS, cancer, and inflammation.
- Oxidative stress is involved in the NF-kappa B signaling pathway, making antioxidants potential inhibitors of NF-kappa B activation.
Purpose of the Study:
- To investigate the effects of catechol derivatives, nitecapone and OR-1246, with known antioxidant properties, on NF-kappa B activation.
- To evaluate the potential of these compounds as therapeutic agents targeting NF-kappa B.
Main Methods:
- Assessing the inhibition of NF-kappa B DNA binding activity by nitecapone and OR-1246.
- Utilizing Jurkat T cells stimulated with tumor necrosis factor-alpha (TNF-alpha) and okadaic acid.
Main Results:
- Both nitecapone and OR-1246 inhibited TNF-alpha-induced NF-kappa B activation in Jurkat T cells.
- Nitecapone exhibited stronger inhibitory effects compared to OR-1246.
- OR-1246's inhibitory mechanism on NF-kappa B activation by TNF-alpha was not solely dependent on direct DNA binding inhibition, as it did not inhibit activation induced by okadaic acid.
Conclusions:
- Catechol derivatives, including nitecapone and OR-1246, can inhibit NF-kappa B transcription factor through multiple mechanisms.
- Nitecapone and OR-1246 show promise as therapeutic agents for conditions involving NF-kappa B dysregulation.